Page 82 - GTM-2-3

Global Translational Medicine Thromboembolism risk in non-small-cell lung cancer

lung cancer. J Thromb Haemost, 6: 601–608. 41. Demirci NY, Turay UY, Ylmaz A, et al., 2011, Vascular events
in lung cancer. Asian Pac J Cancer Prev, 12: 2685–2687.
https://doi.org/10.1111/j.1538-7836.2008.02908.x
42. Pedersen LM, Milman N, 1996, Prognostic significance of
38. Roselli M, Riondino S, Mariotti S, et al., 2014, Clinical thrombocytosis in patients with primary lung cancer. Eur
models and biochemical predictors of VTE in lung cancer. Respir J, 9: 1826–1830.
Cancer Metastasis Rev, 33: 771–789.
https://doi.org/10.1183/09031936.96.09091826
https://doi.org/10.1007/s10555-014-9500-x
43. Fei X, Wang H, Yuan W, et al., 2017, Tissue factor pathway
39. Ay C, Ünal UK, 2016, Epidemiology and risk factors for inhibitor-1 is a valuable marker for the prediction of deep
venous thromboembolism in lung cancer. Curr Opin Oncol, venous thrombosis and tumor metastasis in patients with
28: 145–149. lung cancer. Biomed Res Int, 2017: 8983763.
https://doi.org/10.1097/CCO.0000000000000262 https://doi.org/10.1155/2017/8983763

40. Kadlec J, Skrickova ZM, Merta Z, et al., 2014, The incidence 44. Shiina Y, Nakajima T, Yamamoto T, et al., 2019, The D-dimer
and predictors of thromboembolic events in patients with level predicts the postoperative prognosis in patients with
lung cancer. ScientificWorldJournal, 2014: 125706. non-small cell lung cancer. PLoS One, 14: e0222050.
https://doi.org/10.1155/2014/125706 https://doi.org/10.1371/journal.pone.0222050

Volume 2 Issue 3 (2023) 9 https://doi.org/10.36922/gtm.1027